Critical Comparison: Oruka Therapeutics (ORKA) vs. The Competition

Oruka Therapeutics (NASDAQ:ORKAGet Free Report) is one of 39 publicly-traded companies in the “Diagnostic substances” industry, but how does it weigh in compared to its peers? We will compare Oruka Therapeutics to similar companies based on the strength of its institutional ownership, risk, valuation, earnings, dividends, analyst recommendations and profitability.

Analyst Ratings

This is a breakdown of recent ratings for Oruka Therapeutics and its peers, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oruka Therapeutics 0 0 6 2 3.25
Oruka Therapeutics Competitors 862 808 1350 23 2.18

Oruka Therapeutics presently has a consensus price target of $43.17, indicating a potential upside of 49.47%. As a group, “Diagnostic substances” companies have a potential upside of 38.34%. Given Oruka Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Oruka Therapeutics is more favorable than its peers.

Profitability

This table compares Oruka Therapeutics and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Oruka Therapeutics N/A -20.18% -19.51%
Oruka Therapeutics Competitors -1,887.50% -40.52% -25.94%

Earnings & Valuation

This table compares Oruka Therapeutics and its peers gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Oruka Therapeutics N/A -$5.34 million -4.81
Oruka Therapeutics Competitors $559.88 million $6.13 million -106.37

Oruka Therapeutics’ peers have higher revenue and earnings than Oruka Therapeutics. Oruka Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Risk and Volatility

Oruka Therapeutics has a beta of 0.89, indicating that its share price is 11% less volatile than the S&P 500. Comparatively, Oruka Therapeutics’ peers have a beta of 1.33, indicating that their average share price is 33% more volatile than the S&P 500.

Institutional and Insider Ownership

56.4% of Oruka Therapeutics shares are owned by institutional investors. Comparatively, 44.7% of shares of all “Diagnostic substances” companies are owned by institutional investors. 30.9% of Oruka Therapeutics shares are owned by company insiders. Comparatively, 13.1% of shares of all “Diagnostic substances” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Oruka Therapeutics beats its peers on 10 of the 13 factors compared.

Oruka Therapeutics Company Profile

(Get Free Report)

ARCA biopharma, Inc., a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products. The Company’s business focus combines expertise in cardiovascular pathophysiology, molecular genetics, clinical development and product commercialization. It is currently developing Gencaro (bucindolol hydrochloride), a cardiovascular drug for the treatment of chronic heart failure. The company is based in Broomfield, Colorado.

Receive News & Ratings for Oruka Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oruka Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.